J 2019

Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma

HAJEK, Roman, Michel DELFORGE, Marc S. RAAB, Paul SCHOEN, Lucy DECOSTA et. al.

Základní údaje

Originální název

Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma

Autoři

HAJEK, Roman (203 Česká republika, garant), Michel DELFORGE (56 Belgie), Marc S. RAAB (276 Německo), Paul SCHOEN (756 Švýcarsko), Lucy DECOSTA (826 Velká Británie a Severní Irsko), Ivan SPICKA (203 Česká republika), Jakub RADOCHA (203 Česká republika), Luděk POUR (203 Česká republika, domácí), Sebastian GONZALEZ-MCQUIRE (756 Švýcarsko) a Walter BOUWMEESTER (528 Nizozemské království)

Vydání

British journal of haematology, Hoboken, Wiley-Blackwell, 2019, 0007-1048

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 5.518

Kód RIV

RIV/00216224:14110/19:00112957

Organizační jednotka

Lékařská fakulta

DOI

UT WoS

000480188400001

Klíčová slova anglicky

algorithm; multiple myeloma; overall survival; relapsed; risk stratification

Štítky

Změněno: 17. 2. 2020 10:09, Mgr. Tereza Miškechová

Anotace

V originále

Multiple myeloma (MM) is a malignancy with varying survival outcomes and drivers of disease progression. Existing MM staging tools were developed using data from newly diagnosed patients. As patient characteristics and disease-related factors change between diagnosis and the initiation of second-line (2L) treatment, an unmet need exists for a tool that can evaluate risk of death at first relapse. We have developed a risk stratification algorithm (RSA) using data from patients with MM who were at 2L. Hazard ratios for independent predictors of overall survival (OS) were derived from a Cox models, and individual patient scores were calculated for total risk. K-adaptive partitioning for survival was used to stratify patients into groups based on their scores. Relative risk doubled with ascending risk group; median OSs for patients in group 1 (lowest risk)-4 (highest risk) were 61 center dot 6, 29 center dot 6, 14 center dot 2 and 5 center dot 9 months, respectively. Differences in OS between risk groups were significant. Similar stratification was observed when the RSA was applied to an external validation data set. In conclusion, we have developed a validated RSA that can quantify total risk, frailty risk and disease aggressiveness risk, and stratify patients with MM at 2L into groups with profoundly different survival expectations.